Skip to main content

ResMed Inc. (RMD)

NYSE: RMD · IEX Real-Time Price · USD
267.98 0.48 (0.18%)
Oct 25, 2021 4:00 PM EDT - Market closed
Market Cap39.05B
Revenue (ttm)3.20B
Net Income (ttm)474.51M
Shares Out145.60M
EPS (ttm)3.24
PE Ratio82.71
Forward PE43.29
Dividend$1.59 (0.59%)
Ex-Dividend DateAug 18, 2021
Volume580,670
Open268.00
Previous Close267.50
Day's Range265.20 - 268.36
52-Week Range176.42 - 301.34
Beta0.35
AnalystsHold
Price Target261.33 (-2.5%)
Est. Earnings DateOct 28, 2021

About RMD

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software in...

IndustryHealth Care Equipment & Supplies
IPO DateJun 2, 1995
CEOMichael Farrell
Employees7,970
Stock ExchangeNYSE
Ticker SymbolRMD
Full Company Profile

Financial Performance

In 2021, ResMed's revenue was $3.20 billion, an increase of 8.11% compared to the previous year's $2.96 billion. Earnings were $474.51 million, a decrease of -23.67%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ResMed stock is "Hold." The 12-month stock price forecast is 261.33, which is a decrease of -2.48% from the latest price.

Price Target
$261.33
(-2.48% downside)
Analyst Consensus: Hold

News

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 days ago - Zacks Investment Research

ResMed (RMD) to Report Q1 Earnings: What's in the Cards?

Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).

5 days ago - Zacks Investment Research

3 Leading Healthcare Stocks to Buy in 2021 and Beyond

Three healthcare stocks that have momentum on their side and are good buys right now.

Other symbols:ABBVWBA
6 days ago - The Motley Fool

3 Top Healthcare Stocks to Buy Right Now

Each has its own reason for being in your portfolio.

Other symbols:FLGTJNJ
1 week ago - The Motley Fool

ResMed to Report First Quarter Fiscal 2022 Earnings on October 28, 2021

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2022 on Thursday, Oct...

2 weeks ago - GlobeNewsWire

Here's Why You Should Retain ResMed (RMD) Stock for Now

Investors are optimistic about ResMed (RMD) owing to new product launches in the SDB market and strong sales of mask products.

2 weeks ago - Zacks Investment Research

3 Healthcare Stocks to Buy and Hold for the Next 10 Years

Consistency is the main attraction for these companies.

Other symbols:NVOWST
3 weeks ago - The Motley Fool

ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy

A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients

1 month ago - Zacks Investment Research

ResMed Announces Participation in the Bank of America Global Healthcare Conference

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Bank of ...

1 month ago - GlobeNewsWire

People with Sleep Apnea Live Longer on CPAP in Large, Late-Breaking ResMed-Supported ALASKA Study Presented at ERS

Continued PAP use linked to 39% higher chance of survival over a 3-year period Continued PAP use linked to 39% higher chance of survival over a 3-year period

1 month ago - GlobeNewsWire

Chief Administrative Officer Of Resmed Makes $434.44 Thousand Sell

David Pendarvis, Chief Administrative Officer at Resmed (NYSE:RMD), made a large insider sell on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and E...

1 month ago - Benzinga

President Of Resmed Makes $689.53 Thousand Sell

James Hollingshead , President of  Resmed (NYSE: RMD ), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Comm...

1 month ago - Benzinga

ResMed Announces Participation in the Morgan Stanley 19th Annual Global Healthcare Conference

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th A...

1 month ago - GlobeNewsWire

ResMed Announces SaaS Leadership Change

Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed's SaaS business Change intended to drive rapid digital...

2 months ago - GlobeNewsWire

ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization

ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.

2 months ago - Zacks Investment Research

3 Smartest Healthcare Stocks to Buy With $1,000 Right Now

It doesn't take a brainiac to balance risk and reward.

Other symbols:IDXXVRTX
2 months ago - The Motley Fool

ResMed (RMD) Hits New 52-Week High: What's Behind the Rally?

Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.

2 months ago - Zacks Investment Research

ResMed Launches AirSense 11 PAP Series, Advancing Digital Health in Sleep Apnea Treatment

New digital features designed to make therapy setup and nightly use easier for patients, and help clinicians provide care more efficiently New digital features designed to make therapy setup and nightly...

2 months ago - GlobeNewsWire

Final Trades: Alibaba, Resmed, Marathon Petroleum & more

The 'Halftime Report' traders give their top picks to watch for the second half.

Other symbols:BABAMPC
2 months ago - CNBC Television

ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Down

Increased demand for sleep devices and masks, including recovery of core sleep patient flow, drove ResMed's (RMD) fiscal fourth-quarter growth.

2 months ago - Zacks Investment Research

ResMed (RMD) Q4 Earnings and Revenues Beat Estimates

ResMed (RMD) delivered earnings and revenue surprises of 8.00% and 12.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2021

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

2 months ago - GlobeNewsWire

Betting on These 5 Low-Beta Stocks is Ideal in a Choppy Market

It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. VSTO, CAJ, AMEH, TYL and RMD are the frontrunners.

Other symbols:AMEHCAJTYLVSTO
2 months ago - Zacks Investment Research

6 GARP Stocks to Scoop Up for Maximum Returns

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Other symbols:EWBCHCAKLACLSTRTVTY
2 months ago - Zacks Investment Research

Monday Afternoon Analyst Upgrades and Downgrades: Newell Brands, Teladoc Health, Uber and More

With the trading day nearly halfway over, the broad markets were edging higher, led by the Nasdaq's gain of about 0.5%.

2 months ago - 24/7 Wall Street